Novel Molecules Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 5 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.98 M
- Revenue Growth 166.79%
- Profit Growth 392.68%
- Ebitda 756.40%
- Net Worth 200.48%
- Total Assets 53.90%
About Novel Molecules
Novel Molecules Private Limited (NMPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 December 2019 (Five years and two months 14 days old ). Its registered office is in Ratnagiri, Maharashtra, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹2.98 M.
Pradeep Mulaokar and Sahil Mulaokar serve as directors at the Company.
Company Details
- Location
Ratnagiri, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24297PN2019PTC188316
- Company No.
188316
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Dec 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Novel Molecules?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sahil Mulaokar  | Director | 10-Dec-2019 | Current |
| Pradeep Mulaokar | Additional Director | 14-Aug-2021 | Current |
Financial Performance of Novel Molecules.
Novel Molecules Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 166.79% increase. The company also saw a substantial improvement in profitability, with a 392.68% increase in profit. The company's net worth Soared by an impressive increase of 200.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Novel Molecules?
In 2020, Novel Molecules had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Saga Chemie Private LimitedPradeep Mulaokar is a mutual person
Beta Molecules LlpPradeep Mulaokar and Sahil Mulaokar are mutual person
- Zephyr Speciality Chemicals Private Limited
Pradeep Mulaokar and Sahil Mulaokar are mutual person
Charges (Loans)
₹2.98 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.30 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 Oct 2021 | Others | ₹1.80 M | Open |
| 07 Sep 2021 | Others | ₹1.18 M | Open |
How Many Employees Work at Novel Molecules?
Unlock and access historical data on people associated with Novel Molecules, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Novel Molecules, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Novel Molecules's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
